27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Novavax Inc (NASDAQ:NVAX) has enrolled the first participants in a Phase 1/2 study to test its combined flu and COVID-19 vaccine.
- The trial combines Novavax's recombinant protein-based NVX-CoV2373 and NanoFlu vaccine candidates and patented saponin-based Matrix-M adjuvant in a single formulation (COVID-NanoFlu Combination Vaccine).
- Both NVX-CoV2373 and NanoFlu have previously demonstrated strong results as standalone vaccines in Phase 3 trials.
- Related: Novavax's COVID-19 Vaccine Candidate Showed Immune Response, Protection Against Variants.
- The trial will evaluate the safety, tolerability, and immune response to NanoFlu in 640 healthy adults 50 to 70 years of age.
- Results are expected during the first half of 2022.
- Read Next: Novavax's COVID-19 Vaccine, Flu Shot Co-administration Preserved Efficacy, Likely 'Viable Strategy'.
- Price Action: NVAX stock is down 0.83% at $268.35 during the market session on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!